ResMed Inc
(ASX:RMD) has announced a 7 per cent increase in revenue for the March quarter to $453.9 million, compared to the previous corresponding period.
Revenue increased by 9 per cent on a constant currency basis.
The company which manufactures and sells products to treat sleep aponea says it has seen seven consecutive quarters of device growth, since the launch of its Air Solutions platform.
Cash flow from operations for the quarter was $122.1 million, an increase on the $90.9 million reported in the same quarter last year.
Directors have declared a quarterly dividend of $0.30 per share.
